Lilly (Eli)

Current directors and officers who also hold a role at another S&P 500 company.

• Daniel SkovronskyILMN · Director
• David A. RicksADBE · Director
• Gabrielle SulzbergerMA · Director
• J. Erik FyrwaldIFF · CEO
• Jamere JacksonAZO · CFO
• Jon R. MoellerPG · Chair
• Juan R. LucianoADM · CEO
• Kimberly H. JohnsonTROW · Officer
• Mary Lynne HedleyVEEV · Director
• Ralph AlvarezLOW · Director
• William G. Kaelin, Jr.IQV · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Nov 21, 2025

   On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025. Dr. Bertozzi, 59, is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi will serve on both the Board's Science and Technology Committee and the Ethics and Compliance Committee and will stand for election by Company shareholders at the Company’s annual meeting in May 2026. The Board has determined that Dr. Bertozzi is independent under applicable standards of the New York Stock Exchange and the Company’s director independence guidelines. There are no arrangements or understandings between Dr.

   Read the 8-K filing
2. Nov 19, 2024

   On November 19, 2024, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Jon Moeller as a new member of the Board, effective December 1, 2024. In addition, on November 19, 2024, Karen Walker notified the Board of her resignation from the Board effective December 31, 2024. Starting in 2025, Ms. Walker is expected to collaborate with the Company on certain digital commercial activities. Mr. Moeller, 60, is the Chairman of the Board, President and Chief Executive Officer of Procter & Gamble (“P&G”). Mr. Moeller is a strong leader who has served as an integral part of P&G’s leadership team for over two decades, having held key positions within P&G’s finance, business, and strategy functions. Mr.

   Read the 8-K filing
3. Sep 9, 2024

   On September 9, 2024, Eli Lilly and Company (the “Company” or “Lilly”) announced that the Board of Directors of the Company elected Lucas Montarce, age 47, as executive vice president and chief financial officer of the Company following an internal and external search performed across industries. Since joining Lilly in 2001, Mr. Montarce has held a range of finance leadership roles. Most recently, he served as the president and general manager for the Spain, Portugal and Greece hub, a position he assumed in 2024. Prior to that, Mr. Montarce served as group vice president, controller and chief financial officer of Lilly Research Laboratories since 2021. Other leadership positions he has held with Lilly include: vice president, finance and chief financial officer, Lilly International; and vice president, finance and global chief financial officer, Elanco Health.

   Read the 8-K filing
4. Aug 16, 2024

   On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024. Dr. Runge's decision to retire as a director did not arise from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On August 16, 2024, the Company issued a press release announcing Dr. Runge's retirement from the Board. A copy of the release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

   Read the 8-K filing
5. Jul 10, 2024

   On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry. Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company. During his 29-year career with the Company, Mr. Brooks has held various leadership roles across the Company’s finance organization, including as senior vice president, chief procurement officer, from February 2019 to March 2024, prior to becoming the group vice president, controller and corporate strategy. Previous finance leadership roles held by Mr. Brooks include chief financial officer for Lilly U.S.

   Read the 8-K filing
6. Jun 5, 2024

   On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry. Ms. Ashkenazi will continue to serve at full capacity in her role and as a member of the Company’s Executive Committee through July 2024. An internal and external search for Ms. Ashkenazi’s successor is underway. A copy of the press release announcing the foregoing is attached as Exhibit 99.1 to this Current Report on Form 8-K.

   Read the 8-K filing
7. Mar 17, 2023

   On March 17, 2023, Eli Lilly and Company (the “Company”) entered into a non-competition and non-solicitation agreement with Daniel Skovronsky (the “Agreement”). Consistent with the terms of the Company’s Form of Non-Compete Payment Agreement, Dr. Skovronsky has agreed not to engage in certain competitive activities or solicit anyone who has a business relationship with the Company during the period of his employment and for a period of up to 12 months following termination of employment. Dr. Skovronsky will be entitled to receive payment of up to $5 million (less applicable reductions by the Company and deductions required by law for the payment of wages) in the event that the Company seeks to enforce the terms of the Agreement.

   Read the 8-K filing
8. May 6, 2022

   On May 2, 2022, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Dr. Mary Lynne Hedley as a new member of the class of 2025, effective May 15, 2022. Dr. Hedley, age 59, has been a Senior Scientific Fellow at the Broad Institute of MIT and Harvard since January of 2021. Prior to that, she served as Director, President and Chief Operating Officer at TESARO, Inc., a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. TESARO was acquired by GlaxoSmithKline plc in 2019. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Science Officer of the biotechnology company, Abraxis Bioscience, Inc., responsible for research and development, operations, medical affairs and business development. Dr.

   Read the 8-K filing
9. Aug 25, 2021

   On August 23, 2021, Eli Lilly and Company (the “Company”) entered into a multi-year research collaboration and licensing agreement with Lycia Therapeutics, Inc. (“Lycia”). In connection with the Company’s entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company’s Board of Directors, effective August 23, 2021. Dr. Bertozzi’s decision to resign as a director did not arise from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On August 25, 2021, the Company issued a press release announcing Dr. Bertozzi’s resignation from the Company’s Board of Directors. A copy of the release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

   Read the 8-K filing
10. Aug 17, 2021

    On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021. On August 17, 2021, the Company issued a press release announcing Mr. Zulueta’s retirement and certain other corporate changes. A copy of the release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    Read the 8-K filing
11. Feb 17, 2021

    On February 16, 2021, the Board of Directors of Eli Lilly and Company (the “Company”) elected Kimberly Johnson as a new member of the class of 2022 (with a term expiring at the 2022 annual meeting of shareholders), effective February 16, 2021. The size of the Board of Directors was increased to fifteen, effective February 16, 2021, in connection with the election of Ms. Johnson. Ms. Johnson, age 48, currently serves as Executive Vice President and Chief Operating Officer of the Federal National Mortgage Association (“Fannie Mae”) and is a member of Fannie Mae’s Management Committee. Prior to serving as Executive Vice President and Chief Operating Officer, Ms. Johnson held various leadership positions with Fannie Mae, including Chief Risk Officer. Before joining Fannie Mae in 2006, Ms. Johnson was a Director at Credit Suisse Group AG. Ms.

    Read the 8-K filing
12. Feb 9, 2021

    On February 9, 2021, Eli Lilly and Company (the “Company” or “Lilly”) announced that the Board of Directors of the Company elected Anat Ashkenazi, age 48, as senior vice president and chief financial officer of the Company. Since joining Lilly in 2001, Ms. Ashkenazi has held a range of roles across strategy and finance. Most recently, she served as senior vice president, controller and chief financial officer of Lilly Research Laboratories. In this role, she oversaw the chief financial officers of the Company’s commercial business areas (BioMedicine, Diabetes, Oncology, and International), as well as those for research and development, manufacturing and quality, G&A, and accounting and financial reporting functions. She also led the corporate strategic planning team and business transformation office.

    Read the 8-K filing
13. Jan 14, 2021

    On January 13, 2021, the Board of Directors of Eli Lilly and Company (the “Company”) elected Gabrielle Sulzberger as a new member of the class of 2021, effective January 25, 2021. The size of the Board of Directors was increased to fourteen, effective January 25, 2021, in connection with the election of Ms. Sulzberger. Ms. Sulzberger, age 60, is a strategic advisor to Two Sigma Impact (“Two Sigma”), a New York based private equity firm. Prior to joining Two Sigma, from 2005 to 2018, Ms. Sulzberger was a General Partner of Rustic Canyon/Fontis Partners L.P., a private equity fund based in Pasadena, California focused on socially responsible investing. Ms. Sulzberger has previously served as principal of several private equity funds over her 30-year career in financial services, as well as chief financial officer of several public and private companies. Ms.

    Read the 8-K filing
14. Oct 23, 2019

    Section (b): On October 23, 2019, the company announced that Enrique Conterno, senior vice president, president of Lilly Diabetes, and president of Lilly USA, informed the board of directors of his intent to retire from the company, effective December 31, 2019. A copy of the press release announcing Mr. Conterno's retirement is filed as Exhibit 99.2 to this Form 8-K. Section (e) On October 21, 2019, the Compensation Committee of the Board of Directors of the Company terminated the Company’s Executive Officer Incentive Plan (the “Plan”), effective January 1, 2020. The Plan was approved by shareholders in April 2011 and was designed to facilitate the tax deductibility of annual incentive awards to executive officers under Section 162(m) of the Internal Revenue Code (“Section 162(m)”).

    Read the 8-K filing
15. Jul 11, 2019

    On July 11, 2019, the company announced that Michael J. Harrington, executive vice president and general counsel, informed the board of directors of his intent to retire from the company, effective December 31, 2019. The company is conducting a search to identify Mr. Harrington’s replacement. A copy of the press release announcing Mr. Harrington's retirement is filed as Exhibit 99.1 to this Form 8-K.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.